Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Derek Naccari

Internal Medicine Metairie, LA Medical Doctor

NPI 1871980128 CMS profile 4864680

4315 Houma Blvd Ste 500, Metairie, LA 70006

Open in the dashboard

General payments

$6,923

413 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derek Naccari of Metairie, LA is reported in the CMS Open Payments database as having received $6,923 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,588 89
2024 General $2,013 122
2023 General $1,963 114
2022 General $745 46
2021 General $172 12
2020 General $240 16
2019 General $203 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Naccari
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Derek Naccari were reported at $1,588. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Derek Naccari Internal Medicine median Middle half National median
2019 $203 $159 $48–$570 $163
2020 $240 $119 $33–$402 $114
2021 $172 $135 $37–$521 $132
2022 $745 $141 $42–$496 $149
2023 $1,963 $149 $45–$519 $160
2024 $2,013 $154 $47–$537 $164
2025 $1,588 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,349 100 payments
  2. Lilly USA, LLC $717 55 payments
  3. AstraZeneca Pharmaceuticals LP $659 25 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $542 33 payments
  5. Novo Nordisk Inc $429 28 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $416 24 payments
  7. Amgen Inc. $406 25 payments
  8. GlaxoSmithKline, LLC. $349 19 payments
  9. Exact Sciences Corporation $244 12 payments
  10. Merck Sharp & Dohme Corporation $195 12 payments
  11. Other $1,618 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,838 412 payments
  2. Education $85 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT $689 61 payments
  2. ELIQUIS $616 50 payments
  3. Kerendia $542 33 payments
  4. FARXIGA $511 16 payments
  5. COMIRNATY $503 28 payments
  6. PREVNAR 20 $437 24 payments
  7. ABRYSVO $409 22 payments
  8. MOUNJARO $399 23 payments
  9. PAXLOVID $361 27 payments
  10. Ozempic $354 24 payments
  11. Other $5,557 322 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

8,975

Median for Internal Medicine: 777

Drug cost

$775,675

Median for Internal Medicine: $73,373

Branded share of claims

17.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 122 $140,269
Farxiga Dapagliflozin Propanediol Brand 98 $105,171
Eliquis Apixaban Brand 91 $98,409
Ozempic Semaglutide Brand 84 $95,873
Jardiance Empagliflozin Brand 77 $81,570
Januvia Sitagliptin Phosphate Brand 67 $45,261
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 49 $30,932
Xarelto Rivaroxaban Brand 29 $24,496
Kerendia Finerenone Brand 21 $23,100
Trulicity Dulaglutide Brand 12 $14,587

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$52,844

Of which drugs: $6,625

Medicare patients

297

Average age 75

Services billed

1,000

139 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 29%
Ischemic heart disease 28%
Chronic kidney disease 25%
Atrial fibrillation 19%
Depression 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,609
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,718

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $99
  • Boehringer Ingelheim Pharmaceuticals, Inc. $60
$158 77 —
NURTEC ODT
  • PFIZER INC. $109
$109 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $104
$104 98 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $95
$95 21 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record